Ensign Peak Advisors, Inc Igm Biosciences, Inc. Transaction History

Ensign Peak Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$15.42 - $27.01 $6,322 - $11,074	410 Added 27.7%	1,890 $43,000
Q2 2022 Aug 12, 2022	SELL	$13.27 - $25.5 $602,298 - $1.16 Million	-45,388 Reduced 96.84%	1,480 $27,000
Q4 2021 Feb 11, 2022	SELL	$27.59 - $66.39 $4.1 Million - $9.87 Million	-148,737 Reduced 76.04%	46,868 $1.37 Million
Q3 2021 Nov 12, 2021	SELL	$65.76 - $90.65 $90,288 - $124,462	-1,373 Reduced 0.7%	195,605 $12.9 Million
Q2 2021 Aug 13, 2021	BUY	$57.98 - $96.6 $782,730 - $1.3 Million	13,500 Added 7.36%	196,978 $16.4 Million
Q1 2021 May 12, 2021	BUY	$71.56 - $121.23 $8.95 Million - $15.2 Million	125,038 Added 213.96%	183,478 $14.1 Million
Q4 2020 Feb 12, 2021	SELL	$47.41 - $115.03 $672,842 - $1.63 Million	-14,192 Reduced 19.54%	58,440 $5.16 Million
Q3 2020 Nov 12, 2020	BUY	$43.0 - $84.01 $87,892 - $171,716	2,044 Added 2.9%	72,632 $5.36 Million
Q2 2020 Aug 12, 2020	BUY	$51.3 - $75.21 $150,616 - $220,816	2,936 Added 4.34%	70,588 $5.15 Million
Q1 2020 May 11, 2020	SELL	$31.51 - $73.75 $207,461 - $485,570	-6,584 Reduced 8.87%	67,652 $3.8 Million
Q4 2019 Feb 14, 2020	BUY	$17.25 - $49.51 $1.28 Million - $3.68 Million	74,236 New	74,236 $2.83 Million

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.